Skip to main content

View full-text article in PMC

. 2022 Jan 4;23(1):549. doi: 10.3390/ijms23010549

Table 3.

Therapeutic index calculated by ratio of concentrations that inhibit 50% of healthy and cancerous cells.

Compound	Therapeutic Index
Compound	NHDF/A549	NHDF/MCF-7	NHDF/LoVo	NHDF/LoVo/Dx
4	14.40 ± 0.70 ^a	6.16 ± 0.98 ^a	18.26 ± 1.20 ^a	8.97 ± 3.21
5	15.82 ± 1.78 ^a	9.29 ± 1.29 ^a	16.93 ± 1.34 ^a	7.60 ± 1.50 ^a
6	13.64 ± 1.32 ^a	9.21 ± 0.03 ^a	16.51 ± 2.01 ^a	2.94 ± 0.77 ^a
7	17.71 ± 0.49 ^a	9.42 ± 0.54 ^a	18.35 ± 0.02 ^a	8.88 ± 1.63 ^a
8	17.03 ± 0.34 ^a	7.76 ± 4.27	19.24 ± 0.77 ^a	2.70 ± 0.16 ^a
9	15.86 ± 0.05 ^a	12.10 ± 5.01	18.96 ± 0.73 ^a	4.02 ± 2.04
10	15.26 ± 1.41 ^a	9.49 ± 0.07 ^a	19.16 ± 0.59 ^a	2.84 ± 1.00
11	18.76 ± 0.16 ^a	8.87 ± 5.03	20.49 ± 0.62 ^a	8.89 ± 3.50
12	1.50 ± 0.18 ^a	18.67 ± 3.51 ^a	1.32 ± 0.07 ^a	1.29 ± 0.07 ^a
13	1.32 ± 0.01 ^a	26.92 ± 3.05 ^a	1.50 ± 0.17 ^a	1.37 ± 0.16
Piroxicam	15.01 ± 0.86 ^a	-	19.13 ± 0.87 ^a	15.31 ± 6.67
Meloxicam	16.41 ± 1.55 ^a	-	18.86 ± 0.55 ^a	10.57 ± 1.68 ^a

Note: Data are shown as a mean ± standard deviation. ^a Represents the significance level at p < 0.05.